CNS Neuroscience & Therapeutics

CNS Neuroscience & Therapeutics is an international peer-reviewed journal of neuroscience, clinical pharmacology and therapeutics published by Wiley, founded in 1995 as CNS Drug Reviews and renamed to its current title in 2008, with a 2025 Journal Impact Factor of 6.6 and first-quartile rankings in both Neurosciences and Pharmacology & Pharmacy.《CNS 神经科学与治疗》（CNS Neuroscience & Therapeutics）是一本由（Wiley）出版的神经科学、临床药理学与治疗学国际同行评议期刊，1995 年以（CNS Drug Reviews）之名创刊、2008 年改为现名，2025 年影响因子为 6.6，在神经科学与药理药学两个类别均居 Q1。

Scope

• Original clinical, experimental and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system.发表与中枢神经系统治疗相关的原创临床、实验与转化研究论文，以及综述和具有时效性的新发现报告。
• Clinical pharmacology, drug development and novel methodologies for drug evaluation.临床药理学、药物研发与药物评价新方法。
• Neurological diseases, with named coverage of stroke, Parkinson's disease, Alzheimer's disease and epilepsy.神经系统疾病，明确涵盖脑卒中、帕金森病、阿尔茨海默病与癫痫。
• Psychiatric and related disorders such as depression, schizophrenia and drug abuse, including their phenomenology and pathophysiology.抑郁、精神分裂症与药物滥用等精神及相关障碍，包括其现象学与病理生理学。
• Pharmacologic as well as psychosocial therapeutics for psychiatric and related disorders, reflecting a bench-to-bedside-and-back translational perspective.精神及相关障碍的药物与心理社会治疗，体现从实验台到病床再回到实验台的转化视角。
• Article types include original research articles, reviews, meta-analyses, clinical guidelines, letters to the editor, editorials and special themed issues, all subject to single anonymized peer review.文章类型包括原创研究、综述、荟萃分析、临床指南、致编辑的信、社论与特刊，均经单向匿名同行评议。

History

• The journal was founded in spring 1995 as CNS Drug Reviews, published by Neva Press of Branford, Connecticut, with Alexander Scriabine as founding editor and David Triggle as co-editor, and it ran for thirteen volumes under that title through winter 2007.该刊 1995 年春季以（CNS Drug Reviews）创刊，由康涅狄格州布兰福德的（Neva Press）出版，（Alexander Scriabine）任创刊主编，（David Triggle）任共同编辑，以该刊名出版十三卷直至 2007 年冬。^[1]
• In 2008 the journal was retitled CNS Neuroscience & Therapeutics from volume 14, issue 1, to reflect a broadened scope beyond CNS-related drugs, and Mark H. Pollack took over as editor.2008 年该刊自第 14 卷第 1 期起更名为（CNS Neuroscience & Therapeutics），以反映其超出中枢神经系统药物的拓展范围，（Mark H. Pollack）接任主编。
• Under the new title the journal moved to Wiley-Blackwell, which has published it from Oxford ever since, and it had already reached the top third of neuroscience journals with an impact factor of 3.474 at the time of the change.更名后该刊转由（Wiley-Blackwell）出版至今（编辑部设于牛津），更名时其影响因子已达 3.474，跻身神经科学期刊前三分之一。
• Ding-Feng Su of the Second Military Medical University in Shanghai served as editor in chief for many years, and the journal has since become a fully open access title listed in DOAJ with a CC BY licence and an article processing charge of 4550 US dollars.上海（Second Military Medical University）的（Ding-Feng Su）长期担任主编，该刊此后转为完全开放获取，被 DOAJ 收录，采用（CC BY）许可，文章处理费为 4550 美元。
• The journal is published monthly in a single volume per year and now runs an editorial office in Shanghai, and its impact factor moved from 5.243 in 2021 and 7.035 in 2022 to 5.0 in 2024 and 6.6 in 2025.该刊每年一卷、按月出版，编辑部设于上海，其影响因子由 2021 年的 5.243 与 2022 年的 7.035，变为 2024 年的 5.0 与 2025 年的 6.6。

Editors

• The editor in chief is Xiaoming Hu, Associate Professor in the Department of Neurology of the University of Pittsburgh, whose research seeks to understand how neuroinflammation contributes to neurological disorders and to develop immunotherapy for neuroprotection and brain repair.现任主编为（University of Pittsburgh）神经病学系副教授（Xiaoming Hu），其研究旨在揭示神经炎症如何促成神经系统疾病，并开发用于神经保护与脑修复的免疫疗法。
• Tian-Ming Gao, Professor of Neurobiology at Southern Medical University in Guangzhou and an academician of the Chinese Academy of Engineering, serves as honorary editor in chief.广州（Southern Medical University）神经生物学教授、中国工程院院士（Tian-Ming Gao）任荣誉主编。
• The associate editors span four continents and include Ken Arai of Harvard Medical School, Cesario Borlongan of the University of South Florida, Maurizio Casarrubea of the University of Palermo, Giuseppe Di Giovanni of the University of Malta, Gang Hu of Nanjing Medical University, Peiying Li of Shanghai Jiao Tong University and Yongfu Yu of Fudan University.副编辑遍布四大洲，包括（Harvard Medical School）的（Ken Arai）、（University of South Florida）的（Cesario Borlongan）、（University of Palermo）的（Maurizio Casarrubea）、（University of Malta）的（Giuseppe Di Giovanni）、（Nanjing Medical University）的（Gang Hu）、（Shanghai Jiao Tong University）的（Peiying Li）与（Fudan University）的（Yongfu Yu）等。
• The wider editorial board is strongly international with a large China-based contingent covering neurology, pharmacology and psychiatry, and the journal reports a 17 percent acceptance rate.编委会国际化程度高，其中在中国工作的成员覆盖神经病学、药理学与精神病学等领域，该刊公布的录用率为 17%。
• Peer review is single anonymized, with the editor in chief assigning manuscripts sequentially to associate editors who typically solicit two external reviews, and a decision is usually made within four weeks of receipt.同行评议采用单向匿名方式，主编按顺序将稿件分配给副编辑，副编辑通常邀请两位外部审稿人，一般在收稿后四周内作出决定。
• The editors may expedite review for high-priority manuscripts with fast-track decisions within one week, authors may nominate up to three qualified referees, and submissions are made through the Wiley Research Exchange portal with free-format submission.对高优先级稿件编辑可加快评审，快速决定一般一周内作出，作者可提名至多三位合格审稿人，稿件经（Wiley Research Exchange）门户以自由格式投递。